Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report) reached a new 52-week high on Wednesday . The company traded as high as $11.84 and last traded at $11.78, with a volume of 1011127 shares changing hands. The stock had previously closed at $11.73.
Analyst Ratings Changes
Separately, Canaccord Genuity Group began coverage on Niagen Bioscience in a report on Tuesday, May 27th. They issued a "buy" rating and a $13.00 price objective for the company.
Read Our Latest Analysis on NAGE
Niagen Bioscience Price Performance
The company's 50 day moving average price is $8.37. The stock has a market cap of $906.64 million, a P/E ratio of 67.71 and a beta of 1.94.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
See Also
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
